Pfizer vs Moderna Which Is More Reliable?

Pfizer and Moderna are two leading pharmaceutical companies that have been at the forefront of developing COVID-19 vaccines. As a result, their stocks have seen significant fluctuations in recent months as investors closely monitor the progress of their vaccine distribution and effectiveness. Both companies have experienced ups and downs in the stock market, with Pfizer being a more established player in the pharmaceutical industry, while Moderna is known for its innovative approach to vaccine development. Investors are closely watching how these companies navigate the competitive landscape and regulatory challenges in the coming months.

Pfizer or Moderna?

When comparing Pfizer and Moderna, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Pfizer and Moderna.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Pfizer has a dividend yield of 6.4%, while Moderna has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Pfizer reports a 5-year dividend growth of 4.08% year and a payout ratio of 221.76%. On the other hand, Moderna reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Pfizer P/E ratio at 34.91 and Moderna's P/E ratio at -7.40. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Pfizer P/B ratio is 1.61 while Moderna's P/B ratio is 1.38.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Pfizer has seen a 5-year revenue growth of 0.13%, while Moderna's is 10.71%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Pfizer's ROE at 4.72% and Moderna's ROE at -17.68%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $26.22 for Pfizer and $42.26 for Moderna. Over the past year, Pfizer's prices ranged from $25.20 to $31.54, with a yearly change of 25.16%. Moderna's prices fluctuated between $42.26 and $170.47, with a yearly change of 303.38%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.